Danish pharmaceutical large Novo Nordisk stated Wednesday its internet revenue soared by 51 % final 12 months, pushed by gross sales of common diabetes and weight problems therapies that helped it grow to be Europe’s most precious firm.
The century-old firm reported a internet revenue of 83.7 billion kroner ($12.1 billion), which was greater than the 82.07 billion kroner forecast by analysts surveyed by monetary knowledge agency FactSet.
Novo Nordisk stated gross sales for its diabetes and weight problems therapies surged by 42 % at fixed alternate charges to 215.1 billion kroner final 12 months.
General gross sales rose by 36 % to 232.3 billion kroner in 2023.
“We’re very happy with the robust efficiency in 2023 reflecting that greater than 40 million folks at the moment are benefiting from our progressive diabetes and weight problems therapies,” chief government Lars Fruergaard Jorgensen stated in an announcement.
“We proceed to make progress on our strategic aspirations. Our focus in 2024 shall be on reaching extra sufferers, progressing and increasing our pipeline in addition to the continued important enlargement of our manufacturing capability,” he added.
Novo Nordisk produces Ozempic, an injectable anti-diabetic therapy which turned wildly common on social networks for its slimming properties.
It additionally makes Wegovy, which has the identical energetic ingredient as Ozempic in a distinct dose and was permitted by US regulators to deal with weight problems.
The success of the medicine has led to Novo Nordisk changing into a darling amongst traders who drove up the corporate’s share worth a lot that the corporate turned Europe’s largest group by market capitalization final 12 months.
© 2024 AFP
Quotation:
Weight-loss drug maker Novo Nordisk’s revenue soars 51% (2024, January 31)
retrieved 31 January 2024
from
This doc is topic to copyright. Other than any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.